Xiaohong Yan

492 total citations · 1 hit paper
7 papers, 260 citations indexed

About

Xiaohong Yan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Xiaohong Yan has authored 7 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Xiaohong Yan's work include Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Xiaohong Yan is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Xiaohong Yan collaborates with scholars based in United States, Puerto Rico and South Korea. Xiaohong Yan's co-authors include Joshua K. Sabari, Karen Velastegui, Alexander I. Spira, Rona Yaeger, Minal Barve, Tanios Bekaii‐Saab, Hirak Der‐Torossian, Shubham Pant, Meredith Pelster and Navid Hafez and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Discovery.

In The Last Decade

Xiaohong Yan

7 papers receiving 258 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation

2023 139 citations Tanios Bekaii‐Saab, Rona Yaeger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaohong Yan United States	6	193	85	84	83	47	7	260
Giovanni Burrafato Italy	9	157 0.8×	96 1.1×	139 1.7×	64 0.8×	25 0.5×	13	247
Elisa Sottotetti Italy	11	181 0.9×	94 1.1×	106 1.3×	101 1.2×	21 0.4×	21	285
Sofía del Carmen Spain	9	121 0.6×	86 1.0×	55 0.7×	87 1.0×	60 1.3×	23	248
Wenzhuan Xie China	8	114 0.6×	98 1.2×	109 1.3×	97 1.2×	20 0.4×	18	238
Floriana Nappo Italy	7	141 0.7×	52 0.6×	131 1.6×	56 0.7×	80 1.7×	21	262
Audrey E. Kam United States	7	161 0.8×	70 0.8×	102 1.2×	64 0.8×	93 2.0×	17	247
Rossana Intini Italy	9	233 1.2×	63 0.7×	82 1.0×	59 0.7×	55 1.2×	29	307
Xin‐Gan Qin China	11	96 0.5×	69 0.8×	114 1.4×	139 1.7×	84 1.8×	25	316
Ana León Spain	9	196 1.0×	101 1.2×	70 0.8×	72 0.9×	45 1.0×	23	260
Jean Philippe Metges France	8	224 1.2×	76 0.9×	124 1.5×	110 1.3×	85 1.8×	23	343

Countries citing papers authored by Xiaohong Yan

Since Specialization

Citations

This map shows the geographic impact of Xiaohong Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaohong Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaohong Yan more than expected).

Fields of papers citing papers by Xiaohong Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaohong Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaohong Yan. The network helps show where Xiaohong Yan may publish in the future.

Co-authorship network of co-authors of Xiaohong Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaohong Yan. A scholar is included among the top collaborators of Xiaohong Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaohong Yan. Xiaohong Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pant, Shubham, Byoung Chul Cho, Christos E. Kyriakopoulos, et al.. (2024). Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Investigational New Drugs. 42(5). 547–558. 1 indexed citations

2.

Yaeger, Rona, Nataliya V. Uboha, Tanios Bekaii‐Saab, et al.. (2024). Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery. 14(6). 982–993. 44 indexed citations

3.

Bekaii‐Saab, Tanios, Rona Yaeger, Alexander I. Spira, et al.. (2023). Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation. Journal of Clinical Oncology. 41(25). 4097–4106. 139 indexed citations breakdown →

4.

Gadgeel, Shirish M., Pasi A. Jänne, Alexander I. Spira, et al.. (2023). MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC. Journal of Thoracic Oncology. 18(11). S118–S118. 8 indexed citations

5.

Pant, Shubham, Rona Yaeger, Alexander I. Spira, et al.. (2023). KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS^G12C mutation.. Journal of Clinical Oncology. 41(36_suppl). 425082–425082. 21 indexed citations

6.

Leal, Ticiana, David Berz, Igor I. Rybkin, et al.. (2022). 43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Annals of Oncology. 33. S19–S20. 13 indexed citations

7.

Spira, Alexander I., Gregory J. Riely, Shirish M. Gadgeel, et al.. (2022). KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS^G12C mutation.. Journal of Clinical Oncology. 40(16_suppl). 9002–9002. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact